Advertisement
Screener

OCUGEN, INC. (OCGN) Long-term Debt, Gross

2.8 / 5 stars · 68/120 Roast Me

OCUGEN, INC. Long-term Debt, Gross

OCUGEN, INC. (OCGN) had Long-term Debt, Gross of $31.50 million as of 2026-03-31, per its 10-Q filed 2026-05-08.

Financial Statements › Notes › Debt Instruments

us-gaap:DebtInstrumentCarryingAmount · last filed 2026-05-08

  • 2026-03-31: Long-term Debt, Gross $31.50M.
  • 2025-12-31: Long-term Debt, Gross $31.50M.
  • 2025-09-30: Long-term Debt, Gross $31.50M.
  • 2025-06-30: Long-term Debt, Gross $31.50M.
Period endLong-term Debt, Gross
2026-03-31$31.50M
10-Q · filed 2026-05-08
2025-12-31$31.50M
10-K · filed 2026-03-04
2025-09-30$31.50M
10-Q · filed 2025-11-05
2025-06-30$31.50M
10-Q · filed 2025-08-04
2025-03-31$31.50M
10-Q · filed 2025-05-09
2024-12-31$32.50M
10-K · filed 2025-03-05
2020-12-31$1.92M
10-K · filed 2021-03-19
2020-09-30$3.18M
10-Q · filed 2020-11-06
2020-06-30$6.41M
10-Q · filed 2020-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B